The publication detail shows the title, authors (with indicators showing other profiled authors), information on the publishing organization, abstract and a link to the article in PubMed. This abstract is what is used to create the fingerprint of the publication. If any grants are referenced by the publication, they will be listed here as well.
A comparison of iothalamate-GFR and serum creatinine-based outcomes: acceleration in the rate of GFR decline in the African American Study of Kidney Disease and Hypertension.
Julia Lewis; Tom Greene; Lawrence Appel; Gabriel Contreras; Janice Douglas; Jim Lash; Robert Toto; Fredrick Van Lente; Xuelei Wang; Jackson T Wright; et al. (Profiled Author: Lawrence Appel)
Nephrology Clinical Trials Center, Vanderbilt University Medical Center, 1211 21st Avenue South, 215 Medical Arts Building, Nashville, TN 37232-1371, USA. firstname.lastname@example.org
Journal of the American Society of Nephrology : JASN 2004;15(12):3175-83.
In renal clinical trials, both slope-based and time-to-event renal outcomes have been used. These outcomes are typically based on estimates of GFR obtained using creatinine or iothalamate GFR (iGFR). The African American Study of Kidney Disease and Hypertension (AASK) was a trial in 1094 African Americans with hypertensive nephrosclerosis, which examined the effects of two levels of BP control and three antihypertensive regimens. This study compared the effects of the AASK interventions on outcomes based on serum creatinine with corresponding outcomes based on iGFR using 9742 matched pairs of iGFR and serum creatinine measurements. The iGFR-based outcomes included (1) a time-to-event composite outcome including a 50% GFR decline, ESRD, or death; (2) a composite outcome including a 50% GFR decline or ESRD; (3) mean decline in GFR in the first 3 mo after randomization (acute slope); (4) mean decline in GFR starting 3 mo after randomization (chronic slope); and (5) mean decline in GFR from baseline (total slope). The corresponding creatinine-based outcomes were (1) a composite of doubling of serum creatinine, ESRD, or death and (2) a composite of doubling of serum creatinine or ESRD and acute, chronic, and total slopes defined by the mean change in estimated GFR (eGFR), where eGFR was estimated from a regression equation for GFR depending primarily on serum creatinine and developed in AASK enrollees. Mean changes in iGFR and eGFR were also compared under extended models that allowed for the possibility that the rate of GFR decline may change over time during the chronic phase. an apparent acceleration in rate of decline of renal function over time was found. Subtle differences were observed between effects of the interventions on some of the creatinine and iGFR slope-based outcomes, but the main conclusions of the trial were similar for the serum creatinine and iothalamate-based measurements. This has important implications for the design of clinical trials with renal outcomes.
This section shows information related to the publication - computed using the fingerprint of the publication - including related publications, related experts and related grants with fingerprints representing significant amounts of overlap between their fingerprint and this publication. The red dots indicate whether those experts or terms appear within the publication, thereby showing potential and actual connections.
J Coresh; R D Toto; K A Kirk; P K Whelton; S Massry; C Jones; L Agodoa; F Van LenteAmerican journal of kidney diseases : the official journal of the National Kidney Foundation 1998;32(1):32-42.
Julia J Scialla; Brad C Astor; Tamara Isakova; Huiliang Xie; Lawrence J Appel; Myles WolfJournal of the American Society of Nephrology : JASN 2013;24(1):125-35.
Bo Hu; Crystal Gadegbeku; Michael S Lipkowitz; Stephen Rostand; Julia Lewis; Jackson T Wright; Lawrence J Appel; Tom Greene; Jennifer Gassman; Brad C Astor; et al.Journal of the American Society of Nephrology : JASN 2012;23(4):706-13.
Appears in this Publication
Author of this Publication